HIV research advances with vaccine breakthroughs and long-acting injectables

Researchers from the La Jolla Institute, Scripps Research, and IAVI have reported a breakthrough in HIV vaccine development using a strategy called germline targeting. After 14 years of collaboration, the approach successfully generated broadly neutralizing antibodies in primates, though success was limited to approximately 44% of the animals. While the results are promising, the vaccine's efficacy in preventing infection has not yet been tested in humans.

In parallel, clinical trials are advancing long-acting injectable treatments. The CUATRO study is currently testing new formulations of cabotegravir and rilpivirine in Brazil and other countries. This research aims to extend the dosing interval to once every four months, potentially reducing the frequency to just three cycles per year. This could improve patient privacy and adherence by reducing the burden of daily medication.

Additionally, lenacapavir, a semi-annual injection, has been recommended by the WHO as a highly effective prevention option. However, significant barriers to global access remain. In the United States, costs can exceed $28,000 annually, and organizations like Doctors Without Borders have raised concerns regarding equitable access and pricing agreements in regions like Latin America.